Literature DB >> 20348949

Membrane-bound mucins: the mechanistic basis for alterations in the growth and survival of cancer cells.

S Bafna1, S Kaur, S K Batra.   

Abstract

Mucins (MUC) are high molecular weight O-linked glycoproteins whose primary functions are to hydrate, protect, and lubricate the epithelial luminal surfaces of the ducts within the human body. The MUC family is comprised of large secreted gel forming and transmembrane (TM) mucins. MUC1, MUC4, and MUC16 are the well-characterized TM mucins and have been shown to be aberrantly overexpressed in various malignancies including cystic fibrosis, asthma, and cancer. Recent studies have uncovered the unique roles of these mucins in the pathogenesis of cancer. These mucins possess specific domains that can make complex associations with various signaling pathways, impacting cell survival through alterations of cell growth, proliferation, death, and autophagy. The cytoplasmic domain of MUC1 serves as a scaffold for interaction with various signaling proteins. On the other hand, MUC4 mediates its effect by stabilizing and enhancing the activity of growth factor receptor ErbB2. MUC16, previously known as CA125, is a well-known serum marker for the diagnosis of ovarian cancer and has a key role in stimulation and dissemination of ovarian cancer cells by interacting with mesothelin and galectin. Therefore, herein we discuss the function and divergent mechanisms of MUC1, MUC4, and MUC16 in carcinogenesis in the context of alteration in cell growth and survival.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20348949      PMCID: PMC2879972          DOI: 10.1038/onc.2010.87

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  105 in total

Review 1.  Mucins in cancer: protection and control of the cell surface.

Authors:  Michael A Hollingsworth; Benjamin J Swanson
Journal:  Nat Rev Cancer       Date:  2004-01       Impact factor: 60.716

2.  Multidrug resistance correlates with overexpression of Muc4 but inversely with P-glycoprotein and multidrug resistance related protein in transfected human melanoma cells.

Authors:  Yan Ping Hu; Bushra Haq; Kermit L Carraway; Niramol Savaraj; Theodore J Lampidis
Journal:  Biochem Pharmacol       Date:  2003-05-01       Impact factor: 5.858

3.  Characterization of the oligosaccharides associated with the human ovarian tumor marker CA125.

Authors:  Nyet Kui Wong; Richard L Easton; Maria Panico; Mark Sutton-Smith; Jamie C Morrison; Frank A Lattanzio; Howard R Morris; Gary F Clark; Anne Dell; Manish S Patankar
Journal:  J Biol Chem       Date:  2003-05-06       Impact factor: 5.157

4.  The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation.

Authors:  Thomas Holbro; Roger R Beerli; Francisca Maurer; Magdalena Koziczak; Carlos F Barbas; Nancy E Hynes
Journal:  Proc Natl Acad Sci U S A       Date:  2003-07-09       Impact factor: 11.205

5.  Activation of the pro-survival phosphatidylinositol 3-kinase/AKT pathway by transforming growth factor-beta1 in mesenchymal cells is mediated by p38 MAPK-dependent induction of an autocrine growth factor.

Authors:  Jeffrey C Horowitz; Daniel Y Lee; Meghna Waghray; Venkateshwar G Keshamouni; Peedikayil E Thomas; Hengmin Zhang; Zongbin Cui; Victor J Thannickal
Journal:  J Biol Chem       Date:  2003-10-23       Impact factor: 5.157

6.  MUC16 mucin is expressed by the human ocular surface epithelia and carries the H185 carbohydrate epitope.

Authors:  Pablo Argüeso; Sandra Spurr-Michaud; Cindy L Russo; Ann Tisdale; Ilene K Gipson
Journal:  Invest Ophthalmol Vis Sci       Date:  2003-06       Impact factor: 4.799

7.  Human MUC1 carcinoma antigen regulates intracellular oxidant levels and the apoptotic response to oxidative stress.

Authors:  Li Yin; Yongqing Li; Jian Ren; Hiroaki Kuwahara; Donald Kufe
Journal:  J Biol Chem       Date:  2003-06-25       Impact factor: 5.157

8.  Human DF3/MUC1 carcinoma-associated protein functions as an oncogene.

Authors:  Yongqing Li; Derek Liu; Dongshu Chen; Surender Kharbanda; Donald Kufe
Journal:  Oncogene       Date:  2003-09-04       Impact factor: 9.867

9.  Aberrant expression of MUC3 and MUC4 membrane-associated mucins and sialyl Le(x) antigen in pancreatic intraepithelial neoplasia.

Authors:  Hee-Ug Park; Jong-Woo Kim; Grace E Kim; Han-Ik Bae; Suzanne C Crawley; Stacey C Yang; James R Gum; Surinder K Batra; Karine Rousseau; Dallas M Swallow; Marvin H Sleisenger; Young S Kim
Journal:  Pancreas       Date:  2003-04       Impact factor: 3.327

10.  Clinical evaluation of a new two-site assay for CA125 antigen.

Authors:  V Capstick; G D Maclean; M R Suresh; D Bodnar; S Lloyd; L Shepert; B M Longenecker; M Krantz
Journal:  Int J Biol Markers       Date:  1991 Apr-Jun       Impact factor: 3.248

View more
  157 in total

Review 1.  L-BLP25 as a peptide vaccine therapy in non-small cell lung cancer: a review.

Authors:  Wenjie Xia; Jie Wang; Youtao Xu; Feng Jiang; Lin Xu
Journal:  J Thorac Dis       Date:  2014-10       Impact factor: 2.895

Review 2.  Mucins in the pathogenesis of breast cancer: implications in diagnosis, prognosis and therapy.

Authors:  Partha Mukhopadhyay; Subhankar Chakraborty; Moorthy P Ponnusamy; Imayavaramban Lakshmanan; Maneesh Jain; Surinder K Batra
Journal:  Biochim Biophys Acta       Date:  2011-01-26

3.  Characterization of the Src/Abl hybrid kinase SmTK6 of Schistosoma mansoni.

Authors:  Svenja Beckmann; Steffen Hahnel; Katia Cailliau; Mathieu Vanderstraete; Edith Browaeys; Colette Dissous; Christoph G Grevelding
Journal:  J Biol Chem       Date:  2011-10-19       Impact factor: 5.157

4.  Extracellular leucine-rich repeat proteins are required to organize the apical extracellular matrix and maintain epithelial junction integrity in C. elegans.

Authors:  Vincent P Mancuso; Jean M Parry; Luke Storer; Corey Poggioli; Ken C Q Nguyen; David H Hall; Meera V Sundaram
Journal:  Development       Date:  2012-01-25       Impact factor: 6.868

Review 5.  The use of therapeutic peptides to target and to kill cancer cells.

Authors:  R J Boohaker; M W Lee; P Vishnubhotla; J M Perez; A R Khaled
Journal:  Curr Med Chem       Date:  2012       Impact factor: 4.530

Review 6.  Pathobiological implications of mucin glycans in cancer: Sweet poison and novel targets.

Authors:  Seema Chugh; Vinayaga S Gnanapragassam; Maneesh Jain; Satyanarayana Rachagani; Moorthy P Ponnusamy; Surinder K Batra
Journal:  Biochim Biophys Acta       Date:  2015-08-28

Review 7.  Can we better predict the biologic behavior of incidental IPMN? A comprehensive analysis of molecular diagnostics and biomarkers in intraductal papillary mucinous neoplasms of the pancreas.

Authors:  Kiara A Tulla; Ajay V Maker
Journal:  Langenbecks Arch Surg       Date:  2017-12-07       Impact factor: 3.445

8.  Increased expression of MUC1 and sialyl Lewis antigens in different areas of clear renal cell carcinoma.

Authors:  Małgorzata Borzym-Kluczyk; Iwona Radziejewska; Marzanna Cechowska-Pasko
Journal:  Clin Exp Nephrol       Date:  2014-08-05       Impact factor: 2.801

9.  Endogenous airway mucins carry glycans that bind Siglec-F and induce eosinophil apoptosis.

Authors:  Takumi Kiwamoto; Toshihiko Katoh; Michael Tiemeyer; Bruce S Bochner; Christopher M Evans; William J Janssen; Mary E Brummet; Sherry A Hudson; Zhou Zhu
Journal:  J Allergy Clin Immunol       Date:  2014-12-12       Impact factor: 10.793

10.  Mastoparan is a membranolytic anti-cancer peptide that works synergistically with gemcitabine in a mouse model of mammary carcinoma.

Authors:  Ashley L Hilchie; Andrew J Sharon; Evan F Haney; David W Hoskin; Marcel B Bally; Octavio L Franco; Jennifer A Corcoran; Robert E W Hancock
Journal:  Biochim Biophys Acta       Date:  2016-10-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.